ZURICH, Switzerland and FAIRFIELD, New Jersey, March 13 /PRNewswire-FirstCall/ -- "The new Stonegate Report about Unigene confirms that we are uniquely positioned as the only biopharma company that manufactures peptides by recombinant techniques, while also having oral and nasal delivery systems to administer the peptides. Since the launch of "Fortical" in 2005 with partner Upsher-Smith Laboratories, "Fortical" has captured a near dominant 49% market share of the U.S. nasal calcitonin market that is estimated to be in the $200 million range."
Stonegate Securities, Inc. Unigene Laboratories Inc. (WKN 875852, ISIN
US9047531002, UUL, OTCBB: UGNE)
52-Week Range $1.50 - $2.70
Market Capitalization 157,952,000
Enterprise Value 166,734,000
Primary Shares Outstanding 87,751,000
Insider Ownership 5%
Institutional Ownership 15%
Daily Volume (3-Month Avg.) 94,000
Corporate Headquarters Fairfield, NJ
Unigene is a biopharmaceutical company that focuses on the research,
production and delivery of therapeutic peptides. Its initial focus is on
salmon calcitonin (sCT) and other peptides for the treatment of chronic
bone and joint disorders. Unigene received FDA approval for Fortical(R), a
sCT-based product that addresses the osteoporosis market, in 2005.
Upsher-Smith Laboratories licensed the rights to Fortical(R). In addition,
Unigene has developed a patented manufacturing process for the efficient
production of peptides and patented technologies for the oral and nasal
delivery of peptides. The Company has also licensed the worldwide rights
|SOURCE Unigene Laboratories Inc.|
Copyright©2008 PR Newswire.
All rights reserved